Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm Phase 3 Clinical Study to Investigate the Long-Term Safety of Fezolinetant in Women in China Suffering From Vasomotor Symptoms (Hot Flashes) Associated With Menopause

NCT04451226 is registered in ClinicalTrials.gov with Astellas Pharma China, Inc. as lead sponsor.

NCT NCT04451226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04451226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm Phase 3 Clinical Study to Investigate the Long-Term Safety of Fezolinetant in Women in China Suffering From Vasomotor Symptoms (Hot Flashes) Associated With Menopause
Lead sponsor
Astellas Pharma China, Inc.
Phase
Phase 3
Overall status
Completed
Start date
July 30, 2020
Completion date
June 13, 2022
Enrollment
150 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

hot flashes